Novel αO-conotoxin GeXIVA[1,2] Nonaddictive Analgesic with Pharmacokinetic Modelling-Based Mechanistic Assessment
暂无分享,去创建一个
J. Che | Dongting Zhangsun | S. Luo | Xiaoyu Zhu | Gang Yu | Huanbai Wang | Mei Yuan
[1] Hui Zhang,et al. Lyophilization Serves as an Effective Strategy for Drug Development of the α9α10 Nicotinic Acetylcholine Receptor Antagonist α-Conotoxin GeXIVA[1,2] , 2021, Marine drugs.
[2] A. Sakamoto,et al. Endothelin receptor type A is involved in the development of oxaliplatin-induced mechanical allodynia and cold allodynia acting through spinal and peripheral mechanisms in rats , 2021, Molecular pain.
[3] Yan-yan Chu,et al. Medicinal chemistry, pharmacology, and therapeutic potential of α-conotoxins antagonizing the α9α10 nicotinic acetylcholine receptor. , 2020, Pharmacology & therapeutics.
[4] Ulrich Dirnagl,et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research* , 2020, BMC Veterinary Research.
[5] Esther J Pearl,et al. The ARRIVE guidelines 2.0: Updated guidelines for reporting animal research , 2020, PLoS biology.
[6] Yong-Qing Wang,et al. The Impact of Plasma Protein Binding Characteristics and Unbound Concentration of Voriconazole on Its Adverse Drug Reactions , 2020, Frontiers in Pharmacology.
[7] Dongting Zhangsun,et al. Preclinical research of analgesic αO-conotoxin GeXIVA without addiction side effect. , 2020, Toxicon.
[8] Xiaopeng Zhu,et al. Effects of Cyclization on Activity and Stability of α-Conotoxin TxIB , 2020, Marine drugs.
[9] Taolue Wu,et al. Intra-articular delivery of celastrol by hollow mesoporous silica nanoparticles for pH-sensitive anti-inflammatory therapy against knee osteoarthritis , 2020, Journal of Nanobiotechnology.
[10] D. Craik,et al. Structure and Activity Studies of Disulfide-Deficient Analogues of αO-Conotoxin GeXIVA. , 2020, Journal of medicinal chemistry.
[11] D. Craik,et al. Conotoxins: Chemistry and Biology. , 2019, Chemical reviews.
[12] Dongting Zhangsun,et al. DSPE-PEG Modification of α-Conotoxin TxID , 2019, Marine drugs.
[13] R. Su,et al. The α9α10 Nicotinic Acetylcholine Receptor Antagonist αO-Conotoxin GeXIVA[1,2] Alleviates and Reverses Chemotherapy-Induced Neuropathic Pain , 2019, Marine drugs.
[14] J. Lötsch,et al. Potential biomarkers for persistent and neuropathic pain therapy. , 2019, Pharmacology & therapeutics.
[15] Dongting Zhangsun,et al. Discovery Methodology of Novel Conotoxins from Conus Species , 2018, Marine drugs.
[16] S. Jacob,et al. Dose translation between laboratory animals and human in preclinical and clinical phases of drug development , 2018, Drug development research.
[17] D. Servent,et al. α9‐containing nicotinic acetylcholine receptors and the modulation of pain , 2018, British journal of pharmacology.
[18] Dongting Zhangsun,et al. Effects of serum, enzyme, thiol, and forced degradation on the stabilities of αO‐Conotoxin GeXIVA[1,2] and GeXIVA [1,4] , 2018, Chemical biology & drug design.
[19] Irina Vetter,et al. Methods Used to Evaluate Pain Behaviors in Rodents , 2017, Front. Mol. Neurosci..
[20] E. Glowatzki,et al. RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia , 2017, Front. Cell. Neurosci..
[21] Michael J. O'Donovan,et al. Identification of a novel spinal nociceptive-motor gate control for Aδ pain stimuli in rats , 2017, eLife.
[22] D. Craik,et al. αO-Conotoxin GeXIVA disulfide bond isomers exhibit differential sensitivity for various nicotinic acetylcholine receptors but retain potency and selectivity for the human α9α10 subtype , 2017, Neuropharmacology.
[23] M. Saulino,et al. The Polyanalgesic Consensus Conference (PACC): Recommendations on Intrathecal Drug Infusion Systems Best Practices and Guidelines , 2017, Neuromodulation : journal of the International Neuromodulation Society.
[24] R. Freeman,et al. Neuropathic pain , 1999, The Lancet.
[25] R. Baron,et al. Neuropathic Pain , 2016, Seminars in Neurology.
[26] C. Ghelardini,et al. The α9α10 nicotinic receptor antagonist α-conotoxin RgIA prevents neuropathic pain induced by oxaliplatin treatment , 2016, Experimental Neurology.
[27] Dongting Zhangsun,et al. Anti-hypersensitive effect of intramuscular administration of αO-conotoxin GeXIVA[1,2] and GeXIVA[1,4] in rats of neuropathic pain , 2016, Progress in Neuro-Psychopharmacology and Biological Psychiatry.
[28] D. Craik,et al. Cloning, synthesis, and characterization of αO-conotoxin GeXIVA, a potent α9α10 nicotinic acetylcholine receptor antagonist , 2015, Proceedings of the National Academy of Sciences.
[29] R. Baron,et al. Neuropathic pain: principles of diagnosis and treatment. , 2015, Mayo Clinic proceedings.
[30] A. Dahan,et al. Translational PK–PD modeling in pain , 2012, Journal of Pharmacokinetics and Pharmacodynamics.
[31] W. Lu,et al. Application of model-based methods to characterize exenatide-loaded double-walled microspheres: in vivo release, pharmacokinetic/pharmacodynamic model, and in vitro and in vivo correlation. , 2012, Journal of pharmaceutical sciences.
[32] B. Meibohm,et al. Pharmacokinetics and Pharmacodynamics of Therapeutic Peptides and Proteins , 2012 .
[33] Alec B. O’Connor. Neuropathic Pain , 2012, PharmacoEconomics.
[34] D. Betancur-Ancona,et al. Bioavailability of Bioactive Peptides , 2011 .
[35] N. Absalom,et al. Alpha9 nicotinic acetylcholine receptors and the treatment of pain. , 2009, Biochemical pharmacology.
[36] J. P. Perez Ruixo,et al. Mixed-effects modelling of the interspecies pharmacokinetic scaling of pegylated human erythropoietin. , 2005, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[37] Varun Garg,et al. Comparison of four basic models of indirect pharmacodynamic responses , 1993, Journal of Pharmacokinetics and Biopharmaceutics.
[38] W. Jusko,et al. Pharmacokinetic–Pharmacodynamic Modeling of Tolmetin Antinociceptive Effect in the Rat Using an Indirect Response Model: A Population Approach , 1998, Journal of Pharmacokinetics and Biopharmaceutics.
[39] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[40] B. J. Winterson,et al. Paw withdrawal thresholds and persistent hindlimb flexion in experimental mononeuropathies. , 2003, The journal of pain : official journal of the American Pain Society.
[41] J. Riviere,et al. Mixed-effects modeling of the interspecies pharmacokinetic scaling of oxytetracycline. , 2002, Journal of pharmaceutical sciences.
[42] Editorial: Bioavailability after intramuscular injection. , 1975, The Lancet.